GlassScriptPhysician profile
Kyu S Wang
NPI 1518037340
$2,028.01
in general payments reported to CMS, 2019-2025
18 companies · $249 in 2025
The $249 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2020: $243 · 2021: $584 · 2022: $415 · 2024: $230 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $479.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $385.26 | 2019-2024 | Ozempic, Rybelsus |
| Amgen INC. | $364.83 | 2019-2025 | Evenity, Prolia |
| Amarin Pharma, INC. | $284.51 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $244.00 | 2020-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $178.45 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.12 | 2021-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $122.14 | 2019-2021 | |
| Gilead Sciences, INC. | $70.42 | 2021-2024 | |
| Vifor Pharma, INC. | $41.75 | 2019-2021 | |
| Glaxosmithkline, LLC. | $40.15 | 2025 | Shingrix |
| Esperion Therapeutics, INC. | $39.86 | 2021 | |
| Arbor Pharmaceuticals, INC. | $28.74 | 2021 | |
| Janssen Pharmaceuticals, INC | $27.28 | 2019 | |
| Ardelyx, INC. | $19.26 | 2024 | Ibsrela |
| Merck Sharp & Dohme LLC | $13.82 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $13.64 | 2021 | |
| Eyevance Pharmaceuticals LLC | $13.64 | 2021 | |
| Calliditas Therapeutics US INC. | $12.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyu Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.